Cargando…
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984462/ https://www.ncbi.nlm.nih.gov/pubmed/29855279 http://dx.doi.org/10.1186/s12885-018-4523-2 |